Genetic heterogeneity is common in tumors, explicable by the development of subclones with distinct genetic and epigenetic alterations. We describe an in vitro model for cancer heterogeneity, comprising the diffuse large B-cell lymphoma cell line U-2932 which expresses two sets of cell surface markers representing twin populations flow-sorted by CD20 vs CD38 expression. U-2932 populations were traced to subclones of the original tumor with clone-specific immunoglobulin IgV H 4-39 hypermutation patterns. BCL6 was overexpressed in one subpopulation (R1), MYC in the other (R2), both clones overexpressed BCL2. According to the combined results of immunoglobulin hypermutation and cytogenetic analysis, R1 and R2 derive from a mother clone with genomic BCL2 amplification, which acquired secondary rearrangements leading to the overexpression of BCL6 (R1) or MYC (R2). Some 200 genes were differentially expressed in R1/R2 microarrays including transcriptional targets of the aberrantly expressed oncogenes. Other genes were regulated by epigenetic means as shown by DNA methylation analysis. Ectopic expression of BCL6 in R2 variously modulated new candidate target genes, confirming dual silencing and activating functions. In summary, stable retention of genetically distinct subclones in U-2932 models tumor heterogeneity in vitro permitting functional analysis of oncogenes against a syngenic background.
INTRODUCTION
According to a widely accepted concept, most tumor forms arise from single cells that acquire multiple mutations over time that finally leads to their malignant transformation. 1 However, tumors often show cellular heterogeneity at the chromosomal, genetic and epigenetic level. It has been suggested that in accordance with the Darwinian evolution, malignant clones evolve under the influence of selective forces fueled by mutational alterations. 2 Thereby, therapeutic drugs can be looked upon as one form of selective pressure: efficiently killing the predominant tumor population, therapeutics may be less effective on subclones with other lesions. This may explain why relapsed clones are often genetically distinct from primary diagnostic clones. 3 These observations also explain why 'clonal evolution' is currently such an important topic in cancer and in particular leukemia research. [2] [3] [4] [5] [6] Analysis of the clonal architecture of tumors, including gene expression analysis and the study of genetic and epigenetic characteristics is performed best at the single cell level. 2 However, the necessary techniques are very challenging and only few such studies have been published hitherto. 4, 7 Work with immortalized cell lines providing unlimited supplies of clonal cells would facilitate this work substantially. However, immortalized cell lines are supposed to originate from one cell of the tumor carrying a mutation-or a set of mutations-which allow for continuous growth in vitro. If more than one cell happens to divide in the culture vessel, one clone should eventually outgrow the other. This is the common view.
We show here that the diffuse large B-cell lymphoma (DLBCL) cell line U-2932 consists of two subclones with different IgV H 4-39 hypermutation patterns, which already existed in the primary tumor. The two clones overexpress common (BCL2) and clonespecific oncogenes (BCL6 vs MYC). Overexpression of BCL2, BCL6 and MYC is characteristic of germinal center lymphomas and results from known aberrations. 8 Ectopic regulation of a specific oncogene (for example, BCL6) enables the identification of its transcriptional targets. Genetic and epigenetic mechanisms contribute to the differential expression of genes in the two subclones.
Cell surface marker analysis and cell sorting
Immunophenotyping was done on a FACSCalibur (Becton Dickinson, Heidelberg, Germany). U-2932 subpopulations were sorted on a FACSAriaIII (Becton Dickinson) using FITC labeled CD20 and APC labeled CD38 antibodies (Abs) (Becton Dickinson). Green-fluorescence stained cells were analyzed with PerCP-Cy5.5 labeled CD20, APC labeled CD38 (Becton Dickinson) and APC labeled CD24 Abs (Miltenyi, Bergisch Gladbach, Germany).
Cytogenetic analysis
Spectral karyotyping (SKY) and FISH (fluorescence in situ hybridization) were performed as described previously. 10 Tilepath bacterial artificial chromosome (BAC) clones were sourced from BAC-PAC Resources (Children's Hospital, Oakland, CA, USA), and SKY probes from Applied Spectral Imaging (Edingen, Germany). Probe preparation and labeling were as described previously. 11 Imaging and analysis were performed using an Axioimager D1 microscope system equipped with an a-Plan Apochromat 100 Â objective (Zeiss, Goettingen, Germany) configured to a Spectral Imaging analysis system (Applied Spectral Imaging).
DNA microarray hybridization and analysis
Quality and integrity of total RNA was controlled on Agilent Technologies 2100 Bioanalyzer (Agilent Technologies, Waldbronn, Germany). In all, 500 ng of total RNA were used for biotin labeling according to the 3 0 IVT Express Kit (Affymetrix, Santa Clara, CA, USA). In all, 7.5 mg of biotinylated cRNA were fragmented and placed in a hybridization cocktail containing four biotinylated hybridization controls (BioB, BioC, BioD and Cre) as recommended by the manufacturer. Samples were hybridized to an identical lot of Affymetrix GeneChip HG-U133 2.0 Plus for 16 h at 45 1C.
Steps for washing and SA-PE staining were processed on the fluidics station 450 using the recommended FS450 protocol (Affymetrix). Image analysis was performed on GCS3000 Scanner and GCOS1.2 Software Suite (Affymetrix).
Analysis of microarray data was performed using GeneSpring 11.5.1 (Agilent Technologies). Signal intensities (raw data) were log2 transformed and normalized using RMA.
Gene expression analyses
Quantitative PCR (qRT-PCR) was performed on a 7500 Applied Biosystems (Darmstadt, Germany) real-time PCR system using the manufacturer's protocol. RNA was prepared using the RNeasy Mini kit (Qiagen, Hilden, Germany). For mRNA quantification, reverse transcription was performed using the SuperScript II reverse transcriptase kit (Invitrogen, Karlsruhe, Germany). TaqMan probes (Applied Biosystems) were used to quantify human AICDA (Hs00757808_m1), BCL2 (Hs00153350_m1), BCL2A1 (Hs00187845_m1), BCL6 (Hs00153368_m1), CCND2 (Hs00277041_m1), CD20/MS4A1 (Hs00544819_m1), CD24 (Hs03044178_g1), CD38 (Hs01120071_m1), FBP1 (Hs00983323_m1), ID4 (Hs02912975_g1), LDHA (Hs00855332_g1), VIMENTIN (Hs00185584_m1) expression levels with TATA box binding protein (TBP) as endogenous control. For detection of CD44, CDKN1A, MYC and TP53, SYTO-82 (Molecular Probes, Leiden, The Netherlands) was used as fluorescent dye, ImmoMix (Biline, Luckenwalde, Germany) as PCR master mix, and ribosomal protein S9 (RPS9) as endogenous control. The following primers were used:
0 . Relative expression levels were calculated using the DDCt-method.
Western blot analysis
Samples were prepared as described previously. 12 Anti BCL2, BCL6, MYC and TP53 rabbit antisera were purchased from Cell Signaling (New England Biolabs, Frankfurt, Germany). The GAPDH mouse monoclonal Ab (mAb) was obtained from Abcam (Cambridge, UK). Specific bands on nitrocellulose membranes were visualized with the biotin/streptavidinhorseradish peroxidase system (GE Healthcare, Little Chalfont, UK) in combination with the 'Renaissance Western Blot Chemoluminescence Reagent' protocol (Perkin-Elmer, Waltham, MA, USA). Preparation of recombinant retroviral supernatants and retroviral transduction Retroviral supernatants were generated by calcium phosphate cotransfection of 293T cells using MSCV-BCL6-IRES-GFP (obtained from Addgene (http://www.addgene.org) or MSCV-IRES-GFP (vector control), M57 for gag/pol and pMD.g. Medium was replaced after 12 h by RPMI 1640 medium þ 10% fetal calf serum for an additional 12 h. Retroviral supernatant was collected in RPMI 1640, twice within 24 h, pooled, cleared by low-speed centrifugation and filtered through a 0.45-mm filter. Viral supernatants were centrifuged for 10-16 h at 10 000 r.p.m. at 10 1C for concentration of viral particles.
Each construct was transduced into 5 Â 10 5 U-2932 R2 cells at a multiplicity of infection of about 1. Cells were cultivated for 4 days and GFP þ cells were sorted by a BD FACS Aria (Becton Dickinson). RNA of sorted cells was isolated 10 days after sorting using TRIzol reagent (Invitrogen).
Treatment with DNA demethylating agent 5-Aza-2 -deoxycytidine (5-Aza-dC) 5 -Aza-dC (Sigma Aldrich, Taufkirchen, Germany) dissolved in DMSO was used to verify the effect of methylation on expression of ID4 and VIMENTIN. Cells were seeded at a cell density of 5 Â 10 5 cells/ml, 5-Aza-dC was added at a final concentration of 5 mM. Control cells were treated with 0.05% DMSO. After 2 days, half of the medium was replenished with medium with/without 5-Aza-dC (5 mM). After 3 days, cells were harvested to prepare RNA.
CpG island search
CpG island search was done with Methyl Primer Express v1.0software and EMBOSS CpG plot (http://www.ebi.ac.uk/Tools/emboss/cpgplot/ index.html). The criteria for an island were: GC content 450%; CpG observed vs CpG expected ratio 40.6, length 4100 bp.
Bisulfite sequencing
Bisulfite conversion was performed as described for MSP (methylationspecific PCR). Bisulfite-specific PCR (BSP) amplifying converted DNA independently of the methylation status was performed with the following primers:
0 , vimentin BSP rev 5 0 -AAAATAAAAAATCCCTCAAATC-3 0 ; annealing temperature: 54.8 1C for ID4 BSP, 47 1C for vimentin BSP (35 cycles). PCR products were diluted (1/50) and reamplified (31 cycles). Resulting PCR products were purified, cloned into the pGEM-TEasy vector (Promega) and sequenced. Sequences were evaluated using BiQ Analyzer (http://biq-analyzer.bioinf.mpi.sb.mpg.de) and had to conform to at least 90% bisulfite conversion rate. In addition, identical clones were excluded from the analysis.
Methylation-specific PCR
ID4 and VIMENTIN BSP products were diluted 1/50. MSP was performed using the following primers: 
RESULTS AND DISCUSSION
U-2932, a cell line with two phenotypic subpopulations Deriving from single tumor cells immortalized cell lines usually reveal rather uniform expression patterns of cell surface marker proteins (for example, CD3, CD80 in Figure 1a ). However, in rare cases, individual CD markers show double peaks (CD19, CD20, CD38 in Figure 1a ). Less than 3% (6/256) of the leukemia/ lymphoma cell lines tested by us exhibited these peculiar immunophenotypes. We sorted these cell lines according to their differential CD marker expression levels. Most of the sorted populations did not stably express the selection markers for an extended period of time, but instead regained the original expression pattern of the unsorted cell line. We concluded that in these cases the double peaks were indicative for two activation or differentiation states within a cell line, and that they did not predict the presence of true molecular subclones.
In the following, we show that the DLBCL cell line U-2932 provides an exception: CD20 and CD38 can be used as surrogate markers to identify two phenotypically stable populations of this Figure 1) did not allow enrichment yielding pure and stable subpopulations. After 35 days, the CD20/CD38 expression patterns of these three populations cells were nearly identical, but clearly distinct from R1 (data shown for R1 and for one of the other three gated populations). Reanalysis after 100 days confirmed the existence of two separate populations, R1 (CD20 þ þ /CD38 þ þ ) and R2 (CD20v/CD38v).
cell line and, importantly, these populations typify subclones of the originating tumor.
U-2932 cells were sorted into four populations using CD20 and CD38 expression levels as gating criteria (Supplementary Figure 1) . The CD20 þ þ /CD38 þ þ population (R1) stably kept its expression pattern for 35 days (Figure 1b) . The phenotypes of the other three populations merged quite rapidly, but stayed separate from R1 (exemplarily shown in Figure 1b) . Thus, we concluded that cell line U-2932 consisted of two populations, R1 (CD20 þ þ /CD38 þ þ ) and R2 (CD20v(ariable)/CD38v). Reanalysis after 100 days confirmed the existence of R1 and R2. The stability of the CD markers on the two populations suggested that R1 and R2 might represent two clones of the original tumor and that the differential cell surface marker expression levels of the two cell populations were not merely the result of in vitro B-cell differentiation.
DNA profiling was performed to exclude that cell line U-2932 was contaminated with a second B-cell line, which of course would also explain the appearance of two phenotypes. However, the DNA fingerprints of both subpopulations were identical to each other and also identical to the original tumor DNA (data not shown). In sum, cell line U-2932 consists of two phenotypic subclones.
U-2932 subclones with unique chromosomal aberrations While the cytogenetic kinship of clones R1 and R2 revealed by SKY analysis (Figures 2a and b) is not immediately apparent, their shared pattern of rearrangements point ineluctably to a common clonal origin. Identical or closely related chromosome rearrangements shared by R1/R2 (white boxes in Figure 2a and b) comprised: del(1)(q24) in clone R1 or del(1)(q24)dup (1q11q12) in R2; ider(3)(q10dup(3)q11q25)ins(3;18)(q25;q12q22) qdp(18)(q12q22) in R1 or der(3)t(3;13)(p11;q22)dup(3)(q11q25)ins (3;18)(q25;q12q22)qdp(18)(q12.3q22) in R2; and der(6)t(5;6) (q35;q22) together with der(18)t(1;18)(q13;q12.3) and der(18) t(3;18)(q22;q25)qdp(18)(q12.3;q22) in both R1 and R2. Clonespecific rearrangements (shown inside red boxes and Figures 2a and b) comprised those affecting chromosomes 2, 5, 7, 8, 10, 11 and 15 in R1, and chromosomes 4, 5, 8, 10, 11, 13 ( Â 3), 14, 15 and 19 in R2. These patterns of cytogenetic divergence show that clone R2 is not a daughter of R1, rather that both arose from a putative mother bearing common rearrangements (white boxes).
Comparison of these karyotypes with the G-banded karyogram originally reported for U-2932 shows retention of the following R1 markers: ider(3), der(5)t(3;5)(p11;p11), and der(7)t(2;7)(?q12t(2;14) (?q21;q21), der(11)t(1;11)(q24;q11), while no R2 markers are evident. Additional R1 markers are probably also traceable to the original karyogram (depicted as unassigned chromosomal markers) albeit at low (published) resolution. Thus, the original karyotype of U-2932 most closely represents clone R1 or its close congener. Moreover, the close similarity of the karyotypes published for U-2932 and described here for clone R1 implies that formation of both common and clone-specific rearrangements occurred solely in vivo, that is that both cell lines are genomically stable.
Turning to oncogene rearrangements (Figure 2c and d) , the affinity of clones R1 and R2 becomes immediately apparent. Both clones show extensive genomic amplification (estimated as 6-7 copies per haploid genome) of BCL2, via genomically related chromosome rearrangements: ider(3) in R1; in der(3)t(3;13) plus der(13)t(X;13) in R2, and in der(18)t(3;18) in both. Similarly, BCL6 is present in ider(3) in R1, der(3)t(3;13) plus der(13)t(X;13) in R2, together with N3, and der(18)t(3;18) in both. BCL6 copy numbers were, moderately amplified, estimated as two per haploid genome in both cases. Neither BCL2, nor BCL6 showed genomic rearrangement by FISH using flanking and straddling clones (Figure 2c and d) . Additional FISH analysis, using clones extending farther centromeric and telomeric of BCL6, failed to detect non-canonical rearrangement of this locus in either clone (not shown). While BCL2 and BCL6 displayed closely related configurations, MYC is rearranged in clone 2 only, via formation of classical der(14)t(8;14)(q24;q32), which effects its juxtaposition with IgH (Figure 2d) . Interestingly, no such rearrangement was reported for the original cell line, 15 placing it again close to clone R1.
In summary, both clones R1 and R2 bear extensive chromosome rearrangement, leading to comparable amplification levels of BCL2 (B6-7 Â ), BCL6 (B2 Â ), while R2 alone carries t(8;14) a classical activating rearrangement of MYC in B-cells. Assuming maximum parsimony, rearrangement of MYC occurred subsequent to amplification of BCL2 and BCL6 at a stage when few additional rearrangements (white boxes in Figure 2a and b) were present. Genomic evolution accompanied by formation of two distinct and complex sets of chromosome rearrangement, including that involving MYC in R2 (red boxes in Figures 2a and b) , then led to formation of two genomically distinct, albeit stable, subclones we now recognize as R1 and R2. The latter clone, if then the weaker, may well have escaped detection during the original cytogenetic investigation, raising the question which factor(s) underlie its subsequent emergence.
Both populations of cell line U-2932 with unique primary tumor-specific immunoglobulin hypermutations Cytogenetic analyses revealed differences between R1 and R2, which were consistent with their common derivation from a mother clone. Protein expression patterns of germinal center oncogenes were also consistent with such a notion: while both U-2932 subclones expressed BCL2, only one (R1) overexpressed BCL6, the other (R2) MYC (Figure 3) . Overexpression of BCL2 and MYC could be explained by the cytogenetic findings, respectively, amplification and juxtaposition with IgH, but the overexpression of BCL6 exclusively in R1 still awaited explanation. We did not detect a translocation affecting the BCL6 gene. However, DNA Figure 2 . Cytogenetic analysis. Depicts pseudocolored images obtained by SKY analysis of U-2932 clones R1 (a) and R2 (b). Identical or related chromosome rearrangements present in both subclones are enclosed in white boxes, while red boxes show unrelated markers unique to each subclone, with rearranged homologs placed to the right. Thus, rearrangements affecting chromosomes 1, 3, 6 and 18 (twice) are shared by both clones. On the other hand, those of 2, 5, 7, 8, 10, 11 and 15 are unique to clone R1, and those of chromosomes 4, 5, 8, 10, 11, 13 (thrice), 14, 15 and 19 are unique to R2, evidencing significant divergent chromosome evolution. C/D: Images depict FISH analysis with flanking and straddling BAC clones covering oncogenes BCL6 at 3q27, IGH at 14q32, MYC at 8q24, and BCL2 at 18q21 are shown together with raw SKY images (arrows), illustrating detailed composition of participant marker chromosomes for clones R1 (c) and R2 (d). Thus, for example, der (13) in clone R2 is comprised (top-to-bottom) of material from chromosomes 14, X, 13, 18 and 3. Note genomic amplification of BCL2 in both ider (3) and der(18)t(3;18) present in clone R1, and in der(3)t(3;13), der(13)t(X;13) and der(18)t(3;18) in clone R2-accompanied in all cases by (unamplified) BCL6. Note lack of BCL2 or BCL6 rearrangement and the closely related albeit non-identical compositions of ider(3) vs der(3)t(3;13) in clones R1 and R2, while der(13)t(X;13)-though clearly related to both der(3)/ider(3) and der(18)t(3;18)-is unique to clone R2. Note also rearrangement of IGH with MYC effected by t(8;14)(q24;q32) present in der (14) which was restricted to clone R2 (d), while clone R1 bore unrearranged copies of both genes. RP11 library BAC clones (ordered by mapping coordinates) were as follows: BCL2-215A20 (red), 2270P21 (green), 147G22 (yellow); BCL6-208N14 (red), 211G3 (yellow), 67E18 (green); IGH-1087P8 (red), 815O20 (green), 112H5 (yellow);
MYC-828L6 (red), 440N18 (green), 195G18 (yellow).
sequencing revealed hypermutations within the 5-prime region of this gene exclusively in the BCL6 positive clone R1 (Supplementary Table 1 ). These hypermutations can cause BCL6 overexpression and are frequent in DLBCL. 16 To corroborate whether clones R1 and R2 were derived from one ancestor and to find out whether they already existed in the primary tumor, we exploited the fact that cell line U-2932 carries a rearranged immunoglobulin gene. 15 We confirmed IgV H 4-39 rearrangement for both populations, R1 and R2. The IgV H 4 PCR products were cloned and sequenced. In both populations, 9/10 clones exhibited an IgV H 4-39 rearrangement with 8% somatic hypermutations. We hypothesize that the remaining clone (1/10 in both populations) represents the second rearranged immunoglobulin allele. In both U-2932 populations, all IgV H 4-39 clones carried 15 identical mutations confirming that R1 and R2 originated from one mother clone (blue dots in Figure 4 ). All nine V H 4-39 clones of R1 carried three additional mutations (red triangles in Figure 4) , absent in the R2 clones. Likewise, occurrence of a single mutation was characteristic for all R2 clones (green triangle in Figure 4 ). These results confirmed that R1 and R2 were true subclones of one putative mother clone. To find out whether the clones had been already present in the tumor, we sequenced IgV H 4-39 PCR product from archival patient DNA. All sequenced clones exhibited the 15 mutations that were uniformly present in both populations of the cell line. Confirming the existence of both clones already in the tumor, one of the nine sequenced clones carried the single mutation typical of R2, two clones carried 2/3 mutations typical of R1, while six carried all 3 R1 characteristic mutations. Thus, both populations show an identical set of immunoglobulin hypermutations, but carry also individual mutations, confirming that they originated independently from one mother clone. This occurred in vivo as both, the R1-and the R2-typical immunoglobulin hypermutations, were also found in tumor DNA. In summary, the two populations of cell line U-2932 are characterized by differential expression of germinal center related oncogenes. BCL6 is highly expressed in population R1, MYC in R2. Overexpression of both oncogenes is often observed in DLBCL, the entity from which cell line U-2932 was derived. 8, 15, 17 B-cell lymphomas with cytogenetic abnormalities targeting the MYC oncogene and a second oncogene (for example, BCL2, BCL6) are called 'double-hit' lymphomas. Double-hit DLBCL were described as being highly aggressive. 18 Our data suggest that in the development of the U-2932 tumor, the BCL2 amplification was the first hit and that the two subclones gained BCL6 and MYC alterations at a later time point.
Differential gene expression patterns of the two U-2932 subclones BCL6 and MYC are transcriptional regulators, suggesting that a substantial number of their target genes might be differentially expressed in R1 and R2. Accordingly, expression array analyses showed 4200 genes differentially regulated in R1 (BCL6 þ ) and R2 (MYC þ ). Prominent were contrasting expression patterns of a raft of cell surface markers (Figure 5a ). Interestingly, several have recently been shown to discriminate germinal center light and dark zone cells. 19 In general, the gene expression profiles of primary DLBCL cells resemble those of light zone cells. 19 While this is also the case for population R1, R2 cells show the dark zone typical expression: CD40 low , CD83 low , CXCR4 high , ICAM1 low and SLAMF1 low (Figure 5a) . Thus, U-2932 populations R1 and R2 transcriptionally model light and dark zone cells, with the important caveat that not all germinal center zone-typical genes are differentially expressed in R1 and R2, notably cell cycle-related genes. Cell-cycle genes represent an exception to the transcriptional faithfulness with which cell lines model their tumors of origin, as evidenced here by the fact that R1 and R2 show identical growth curves, in this respect unlike primary dark and light zone cells ( Supplementary Figure 2A and B) .
Interestingly, one of the zone-identifying genes (CXCR4) had been described as a suppressive BCL6 target. 19, 20 In accordance with this notion, CXCR4 was high in the BCL6 negative population R2, lower in the BCL6 positive population R1 (Figure 5a ). Expression of CD38-one of our sort markers-was positively correlated to BCL6 and of which it is a known target: 16 while highly expressed in the BCL6 positive U-2932 subclone R1, CD38 was low in BCL6 negative R2 cells (Figure 5a ). Thus, array data suggest that BCL6 might exert opposing effects on the transcription of CXCR4 and CD38.
Ectopic expression of BCL6 in U-2932 subpopulation R2 identifies potential target genes To ascertain whether BCL6 played the dual induced/repressor roles posited above, we ectopically expressed BCL6 in population R2. Although not all reported BCL6 targets were regulated (for example, CCND2, CD44, CDKN1A, TP53), 4150 genes responded (partially shown in Figures 5a and b) . [20] [21] [22] The B-cell marker CD24 exemplifies a BCL6 repressed gene: initially highly expressed in the BCL6 negative R2 clone, CD24 was downregulated upon ectopic BCL6 expression (Figures 5b and 6a) . Accordingly, CD24 was low in the BCL6 positive population R1 (Figures 5b and 6a) . Although primarily a suppressor, several genes were stimulated by BCL6 (Figure 5b) . Interestingly, among these were included CD20 and CD38, our sort markers (Figures 5b and 6a ). CD20 and CD38 levels in transfected R2 cells did not reach R1 levels, attributable to modest BCL6 protein expression in the transfected R2 cells (Supplementary Figure 3) . These results suggested that CD20 and CD38 were not just surrogate markers, as originally assumed, but upregulation in R1 cells is a direct consequence of the high BCL6 levels in this population.
Not only cell surface proteins were upregulated by BCL6. BCL2-related protein A1 (BCL2A1), forkhead box G1 (FOXG1), fructose-1,6-bisphosphatase (FBP1) and lactate dehydrogenase (LDHA) were highly expressed in BCL6 positive R1 cells, lower in BCL6 negative R2 cells, and upregulated after BCL6 transfection (Figures 5b and 6b) . One of these genes (BCL2A1) had been described as repressive target of BCL6. 23 Our data suggest that BCL6 might also act as inducer of BCL2A1. LDHA and FBP1 play antithetic roles in the process of aerobic production of lactic acid in tumor cells, namely the Warburg effect. 24 We harvested cell culture supernatants of the two populations of cell line U-2932 to find out whether they differ in their capacity to produce lactic acid. Population R1 secreted roughly twice as much lactic acid as R2 (Supplementary Figure 2C) . The growth curves of both populations were undistinguishable, confirming that the elevated lactic acid levels in R1 were due to a higher Warburg effect and not just the result of proliferative differences (Supplementary Figure 2A and B) . Further studies will examine whether BCL6 directly regulates LDHA and FBP1, therefore being responsible for the high lactic acid levels in R1. These findings illustrate how U-2932 subpopulations can be used as models for functional oncogene studies.
Epigenetic regulation of genes The differential expression of genes in tumor subclones is not only the result of aberrant expression of oncogenes/tumor suppressor genes, but also that of aberrant epigenetic changes. Epigenetic changes are more frequent than mutations and are relevant to tumor evolution. 2, 25 To elucidate whether epigenetic mechanisms contributed to the differential gene expression of R1 and R2, both cell populations were treated with the DNA demethylating agent 5-Aza-2 0 -deoxycytidine (Aza). Expression array analyses were performed to screen for genes that were (i) silenced in one and highly expressed in the other population, and (ii) inducible by Aza. For R2, a list of genes fulfilling these requirements was readily recognizable including ID1, ID2, ID4, STAT1, HES1 and SOCS1 (Figure 5c ). In R1, the effects of DNA demethylation were less profound. Expression of VIMENTIN and IKZF2 was affected by Aza, but not to the extent of the genes triggered in R2 (Figure 5c ). VIMENTIN and ID4 were chosen as candidate genes for epigenetic regulation since both carry CpG islands in their 5-prime regions and are standard methylation biomarkers. 26, 27 Sequencing of bisulfite converted DNA confirmed that ID4 exhibited the inverse correlation between promoter methylation and gene expression that indicates epigenetic regulation (Figure 7a) . Furthermore, qRT-PCR confirmed that Aza induced ID4 expression (Table 1, R2) . VIMENTIN expression was induced by DNA demethylation, as well. However, this effect was rather weak (Table 1, R1) . Furthermore, we did not observe stronger VIMENTIN methylation in R1 (VIMENTIN low) than in R2 (VIMENTIN high) (Figure 7b ). These data suggested that the effect of demethylation on VIMENTIN expression was indirect, while ID4 was directly regulated by promoter methylation. 
CONCLUSION
In summary, the differential gene expressions in the two populations of cell line U-2932 are caused by genetic and epigenetic changes, mechanisms that are also responsible for the evolution of tumor subclones.
2 Both U-2932 populations overexpress one common (BCL2) and one subclone-specific oncogene (BCL6 vs MYC). Our findings invite comparison with those of Snuderl et al., 28 which showed that in a brain tumor three different subpopulations respectively carried activating mutations in receptor kinases EGFR, MET and PDGFRA, consistent with independently evolving subclones acquiring diverse second or subsequent hits, thus mimicking Darwinian selection. 28 In both cases, mosaic tumors pose significant challenges for conventional notions of 'intelligent' therapies, which aim at the selective targeting of specific oncogenes. The two U-2932 populations provide novel tools to study both the function of BCL2, BCL6 and MYC in DLBCL, and their combined therapeutic targeting. In contrast to primary tumor cells, the cell line subpopulations are not contaminated with bystander cells. Another advantage is their unlimited supply, allowing techniques usually denied to investigations restricted to primary cells, including ectopic regulation of the genes of interest. Representing subclones of the original tumor, the two U-2932 populations will be optimal tools to study the function of oncogenes in an identical genetic background. qRT-PCR was performed to verify mRNA expression of BCL6, known BCL6 targets (black) and genes with CpG island (red); n.d., not done.
